EAM
IMCR icon

Exome Asset Management’s Immunocore IMCR Stock Holding History

Exome Asset Management’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-76,750
Closed -$2.66M – 66
2025
Q4 		$2.66M Buy
+76,750
New +$2.71M 1.27% 34

Other funds holding IMCR

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Exome Asset Management's IMCR Position: Q1 2026 in Review

Exome Asset Management sold out of Immunocore (IMCR) in Q1 2026, closing a stake of 76,750 shares — an estimated $2.66M sold.

Exome Asset Management first reported a position in IMCR in Q4 2025 and held it in 1 quarter. The position peaked at $2.66M in Q4 2025. 142 funds tracked by Wall St. Rank hold IMCR as of Q1 2026.

  • Exome Asset Management reported no remaining Immunocore position as of Q1 2026 after selling out during the quarter.
  • Exome Asset Management sold 76,750 Immunocore shares in Q1 2026, an estimated $2.66M.
  • Exome Asset Management first reported a position in Immunocore in Q4 2025 and held it in 1 quarter.
  • Exome Asset Management's Immunocore position peaked at $2.66M in Q4 2025.
  • 142 funds tracked by Wall St. Rank held Immunocore as of Q1 2026.

Based on Exome Asset Management's 13F filing for Q1 2026, filed 15 May 2026.